A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy
S1418 Step 1 Registration is permanently closed to accrual effective June 30, 2021, at 12:oo pm Pacific Time.
S1418 Step 2 Registration is permanently closed to accrual effective August 21, 2021, at 11:59 pm Pacific Time.
Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006, is permanently closed to accrual.
